6vyb
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='6vyb' size='340' side='right'caption='[[6vyb]], [[Resolution|resolution]] 3.20Å' scene=''> | <StructureSection load='6vyb' size='340' side='right'caption='[[6vyb]], [[Resolution|resolution]] 3.20Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[6vyb]] is a 3 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6VYB OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6VYB FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6vyb]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/Wcpv Wcpv]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6VYB OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6VYB FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6vyb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6vyb OCA], [http://pdbe.org/6vyb PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6vyb RCSB], [http://www.ebi.ac.uk/pdbsum/6vyb PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6vyb ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6vyb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6vyb OCA], [http://pdbe.org/6vyb PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6vyb RCSB], [http://www.ebi.ac.uk/pdbsum/6vyb PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6vyb ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination. | ||
| + | |||
| + | Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.,Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D Cell. 2020 Mar 6. pii: S0092-8674(20)30262-2. doi: 10.1016/j.cell.2020.02.058. PMID:32155444<ref>PMID:32155444</ref> | ||
| + | |||
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 6vyb" style="background-color:#fffaf0;"></div> | ||
| + | == References == | ||
| + | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| + | [[Category: Wcpv]] | ||
[[Category: McGuire, A T]] | [[Category: McGuire, A T]] | ||
[[Category: Park, Y J]] | [[Category: Park, Y J]] | ||
Revision as of 10:50, 27 March 2020
SARS-CoV-2 spike ectodomain structure (open state)
| |||||||||||
